Cardiovascular Health

Latest News


CME Content


One of the most common questions from prescribers that I have answered in the past year concerns how to convert from 1 anticoagulant to anothe

Preliminary results of an ongoing post-marketing study examining Janssen Pharmaceuticals' rivaroxaban (Xarelto) in patients with non-valvular atrial fibrillation (NVAF) indicate that the anti-clotting drug's safety in real-world settings is consistent with the findings of previous phase 3 clinical trials.